BGM1812 vs cagrilintide/semaglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin/calcitonin receptor (dual) · full Obesity pipeline

BGM1812

Developed by BrightGene Bio-Medical Technology

Phase 2 in Obesitypeptide
Weak signal

NCT07224399 · Phase 1 · completed

A randomised, double-blind, placebo-controlled single- and multiple-ascending-dose Phase 1 study in 60 participants with BMI 28.6 to 36.2. Its primary endpoint is safety and tolerability, with weight loss only a secondary endpoint, so it is not efficacy evidence. The sponsor reports no serious adverse events and placebo-adjusted weight loss of 0.2% to 9.2%.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: August 2027 · NCT07918625 (registry estimate)

Reported efficacy

Number of treatment adverse events (Predose up to 6 weeks (Part A) & 9 weeks (Part B)): Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026) (not_applicable)

Result source: NCT07224399

cagrilintide/semaglutide · CagriSema

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

Next expected readout: March 2027 · NCT07011667 (registry estimate)

Reported efficacy

Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)

Result source: NCT05394519

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBGM1812cagrilintide/​semaglutide
Body weight, % change—Not reported-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925
Weight loss of 5% or more—Not reported—Not posted · NCT05996848
Weight loss of 10% or more—Not reported—Not posted · NCT05996848
Waist circumference, change (cm)—Not reported—Not posted · NCT05996848

Body weight, % change

BGM1812
—Not reported
cagrilintide/​semaglutide
-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925

Weight loss of 5% or more

BGM1812
—Not reported
cagrilintide/​semaglutide
—Not posted · NCT05996848

Weight loss of 10% or more

BGM1812
—Not reported
cagrilintide/​semaglutide
—Not posted · NCT05996848

Waist circumference, change (cm)

BGM1812
—Not reported
cagrilintide/​semaglutide
—Not posted · NCT05996848
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BGM1812
Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026) NCT07224399 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide/semaglutide

Weight -13.7% vs -3.4% placebo @ 68wk
percent change · % of baseline
NCT05394519 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-18.4% vs -11.9% semaglutide alone @ 68wk
NCT05813925 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM1812's landscape · cagrilintide/semaglutide's landscape